SA93140384B1 - كربامات الفينيل - Google Patents

كربامات الفينيل Download PDF

Info

Publication number
SA93140384B1
SA93140384B1 SA93140384A SA93140384A SA93140384B1 SA 93140384 B1 SA93140384 B1 SA 93140384B1 SA 93140384 A SA93140384 A SA 93140384A SA 93140384 A SA93140384 A SA 93140384A SA 93140384 B1 SA93140384 B1 SA 93140384B1
Authority
SA
Saudi Arabia
Prior art keywords
ethyl
pharmaceutically acceptable
compound
free base
carbamate
Prior art date
Application number
SA93140384A
Other languages
Arabic (ar)
English (en)
Inventor
البرت اينز
Original Assignee
نوفارتيس ايه جي
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6322236&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SA93140384(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by نوفارتيس ايه جي filed Critical نوفارتيس ايه جي
Publication of SA93140384B1 publication Critical patent/SA93140384B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/44—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SA93140384A 1987-03-04 1993-11-29 كربامات الفينيل SA93140384B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3706914 1987-03-04
GB8804888A GB2203040C (en) 1987-03-04 1988-03-01 Phenyl carbamate

Publications (1)

Publication Number Publication Date
SA93140384B1 true SA93140384B1 (ar) 2006-04-04

Family

ID=6322236

Family Applications (1)

Application Number Title Priority Date Filing Date
SA93140384A SA93140384B1 (ar) 1987-03-04 1993-11-29 كربامات الفينيل

Country Status (29)

Country Link
US (1) US5602176A (cg-RX-API-DMAC10.html)
JP (3) JP2625478B2 (cg-RX-API-DMAC10.html)
KR (1) KR0133686B1 (cg-RX-API-DMAC10.html)
AT (1) AT394190B (cg-RX-API-DMAC10.html)
AU (1) AU618949B2 (cg-RX-API-DMAC10.html)
BE (1) BE1001467A3 (cg-RX-API-DMAC10.html)
CA (1) CA1307003C (cg-RX-API-DMAC10.html)
CH (1) CH675720A5 (cg-RX-API-DMAC10.html)
CS (1) CS411091A3 (cg-RX-API-DMAC10.html)
CY (1) CY1735A (cg-RX-API-DMAC10.html)
DK (1) DK175762B1 (cg-RX-API-DMAC10.html)
ES (1) ES2010527A6 (cg-RX-API-DMAC10.html)
FI (1) FI89165C (cg-RX-API-DMAC10.html)
FR (1) FR2611707B1 (cg-RX-API-DMAC10.html)
GB (1) GB2203040C (cg-RX-API-DMAC10.html)
GR (1) GR1000023B (cg-RX-API-DMAC10.html)
HK (1) HK110093A (cg-RX-API-DMAC10.html)
HU (1) HU201906B (cg-RX-API-DMAC10.html)
IE (1) IE61714B1 (cg-RX-API-DMAC10.html)
IL (1) IL85609A (cg-RX-API-DMAC10.html)
IT (1) IT1219853B (cg-RX-API-DMAC10.html)
LU (2) LU87150A1 (cg-RX-API-DMAC10.html)
MY (1) MY103225A (cg-RX-API-DMAC10.html)
NL (1) NL195004C (cg-RX-API-DMAC10.html)
NZ (1) NZ223714A (cg-RX-API-DMAC10.html)
PT (1) PT86875B (cg-RX-API-DMAC10.html)
SA (1) SA93140384B1 (cg-RX-API-DMAC10.html)
SE (1) SE8800731L (cg-RX-API-DMAC10.html)
ZA (1) ZA881584B (cg-RX-API-DMAC10.html)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL195004C (nl) * 1987-03-04 2003-11-04 Novartis Ag Fenylcarbamaat bevattend farmaceutisch preparaat.
AU2224195A (en) * 1994-04-15 1995-11-10 Masaomi Iyo Medicinal composition for treating tardive dyskinesia and utilization thereof
EP0966435B1 (en) 1996-12-18 2005-04-06 Teva Pharmaceutical Industries, Ltd. Aminoindan derivatives
US6251938B1 (en) 1996-12-18 2001-06-26 Teva Pharmaceutical Industries, Ltd., Phenylethylamine derivatives
JP4116085B2 (ja) * 1996-12-18 2008-07-09 テバ・ファーマシューティカル・インダストリーズ・リミテッド フェニルエチルアミン誘導体
GB9800526D0 (en) 1998-01-12 1998-03-11 Ciba Geigy Ag Organic compounds
US6316023B1 (en) * 1998-01-12 2001-11-13 Novartis Ag TTS containing an antioxidant
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
CZ302888B6 (cs) 1998-10-01 2012-01-11 Novartis Ag Orální farmaceutický prípravek obsahující rivastigmin a použití rivastigminu
US20040209849A1 (en) * 1998-11-27 2004-10-21 Sanochemia Pharmazeutika Aktiengesellschaft Use of effectors of the central cholinergic nervous system for treatment of delirium
WO2000033840A1 (en) * 1998-12-11 2000-06-15 Bonnie Davis Use of acetylcholinesterase inhibitors on the modulation of the hypothalamic-pituitary-gonadal axis
GB9923045D0 (en) * 1999-09-29 1999-12-01 Novartis Ag New oral formulations
US6534541B1 (en) 1999-10-19 2003-03-18 Novartis Ag Treatment of ocular disorders
WO2001078721A1 (en) * 2000-04-13 2001-10-25 Mayo Foundation For Medical Education And Research Aβ42 LOWERING AGENTS
US20040010038A1 (en) * 2002-02-27 2004-01-15 Eran Blaugrund Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
CZ293014B6 (cs) * 2002-10-24 2004-01-14 Léčiva, A.S. Způsob výroby (-)-(S)-3-[1-(dimethylamino)ethyl]fenyl-N-ethyl-N-methylkarbamátu
MXPA04006900A (es) * 2002-10-24 2004-10-15 Merz Pharma Gmbh & Co Kgaa Politerapia que utiliza derivados de 1-aminociclohexano e inhibidores de acetilcolinesterasa.
EP1603548A4 (en) * 2003-02-05 2007-10-10 Myriad Genetics Inc METHOD AND COMPOSITION FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
US7521481B2 (en) * 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
US20050042284A1 (en) * 2003-07-11 2005-02-24 Myriad Genetics, Incorporated Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease
AU2004285893B2 (en) 2003-10-21 2011-12-15 Colucid Pharmaceuticals, Inc. Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents
GB2409453A (en) * 2003-12-24 2005-06-29 Generics Process for the preparation of aminoalkyl phenylcarbamates
WO2006001877A2 (en) * 2004-04-13 2006-01-05 Myriad Genetics, Inc. Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
AU2005241023A1 (en) * 2004-04-29 2005-11-17 Keystone Retaining Wall Systems, Inc. Veneers for walls, retaining walls and the like
EP1779867A4 (en) * 2004-07-01 2009-12-02 Eisai R&D Man Co Ltd MEANS FOR PROMOTING NERVE REVENERATION
BRPI0514303A (pt) * 2004-08-11 2008-06-10 Myriad Genetics Inc composição farmacêutica e método para tratar distúrbios neurodegenerativos
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
ES2615487T3 (es) * 2004-11-08 2017-06-07 Emcure Pharmaceuticals Limited un método eficaz para la preparación de (S)-3-[(1-dimetilamino)etil]-fenil-N-etil-N-metil-carbamato
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
EP1909777A2 (en) * 2005-07-22 2008-04-16 Myriad Genetics, Inc. High drug load formulations and dosage forms
ES2267399B1 (es) 2005-08-04 2008-02-01 Ragactives, S.L. Procedimiento para la obtencion de carbamatos de fenilo.
JP5116679B2 (ja) 2005-09-15 2013-01-09 株式会社ソニー・コンピュータエンタテインメント 強度のコンピュータ画像および音声処理、ならびにコンピュータプログラムとインタフェースするための入力装置
TWI389709B (zh) 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
EP1956904B1 (en) * 2005-12-09 2017-04-12 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Low-dose ladostigil for the treatment of mild cognitive impairment
TW200744576A (en) * 2006-02-24 2007-12-16 Teva Pharma Propargylated aminoindans, processes for preparation, and uses thereof
US7767843B2 (en) * 2006-03-02 2010-08-03 Apotex Pharmachem Inc. Process for the preparation of phenylcarbamates
US20080033045A1 (en) * 2006-07-07 2008-02-07 Myriad Genetics, Incorporated Treatment of psychiatric disorders
EP2054373B1 (en) * 2006-08-17 2010-06-30 Alembic Limited Improved process for the preparation of rivastigmine
WO2008037433A1 (en) 2006-09-29 2008-04-03 Synthon B.V. Process for making aminoalkylphenyl carbamates and intermediates therefor
EP2420235A1 (en) 2006-10-27 2012-02-22 Medivation Neurology, Inc. Methods and combination therapies for treating alzheimer's disease
EP1942100A1 (en) * 2007-01-04 2008-07-09 Krka Tovarna Zdravil, D.D., Novo Mesto Amorphous and crystalline forms of rivastigmine hydrogentartrate
WO2008097546A2 (en) * 2007-02-02 2008-08-14 Colucid Pharmaceuticals, Inc. Compounds that inhibit cholinesterase
US8013181B2 (en) * 2007-04-10 2011-09-06 Dr. Reddy's Laboratories Limited Preparation of rivastigmine and its salts
WO2008124969A1 (en) * 2007-04-16 2008-10-23 Topharman Shanghai Co., Ltd. Preparation method of rivastigmine and its intermediates
US7884121B2 (en) * 2007-06-11 2011-02-08 Apotex Pharmachem Inc. Process for the preparation of phenylcarbamates
CN101795683A (zh) * 2007-07-18 2010-08-04 科露西德医药品公司 用于促进警醒症的方法
US8593728B2 (en) * 2009-02-19 2013-11-26 Toyota Motor Engineering & Manufacturing North America, Inc. Multilayer photonic structures
US20090082436A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched rivastigmine
EP2233465B1 (en) 2008-01-10 2017-06-28 Shanghai Institute of Pharmaceutical Industry Preparation method of rivastigmine, its intermediates and preparation method of the intermediates
EP2349976B1 (en) 2008-08-25 2012-12-26 Jubilant Life Sciences Limited A process for producing (s)-3-[(1-dimethylamino)ethyl]phenyl-n-ethyl-n-methyl-carbamate via novel intermediates
US20100087768A1 (en) * 2008-10-02 2010-04-08 Forlano Paula Transdermal drug delivery system for liquid active ingredient
GB0823554D0 (en) * 2008-12-24 2009-01-28 Novartis Ag Process for the preparation of optically active compounds using transfer hydrogenation
CN101823970B (zh) * 2009-03-03 2013-05-08 江苏恩华药业股份有限公司 卡巴拉汀及其中间体的合成方法
US10076502B2 (en) 2009-12-22 2018-09-18 Luye Pharma Ag Transdermal therapeutic system for administering rivastigmine or derivatives thereof
NO2515886T3 (cg-RX-API-DMAC10.html) 2009-12-22 2018-09-08
ES2363395B1 (es) * 2010-01-20 2012-02-23 Farmalider, S.A. Composición farmacéutica l�?quida de rivastigmina o de una de sus sales de adición de �?cido para la administración por v�?a oral.
CA2789014C (en) * 2010-02-09 2019-01-15 Michela Gallagher Methods and compositions for improving cognitive function
NZ601729A (en) 2010-03-29 2013-10-25 Novartis Ag Composition comprising the amyloid beta 1-6 peptide coupled to a virus-like particle and an adjuvant
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
WO2011151669A1 (en) 2010-06-02 2011-12-08 Jubilant Life Sciences Limited Process for producing enantiomerically enriched isomer of 3-(1-aminoethyl) phenyl derivative and employing the same to produce rivastigmine or its pharmaceutically acceptable salt
HUE038434T2 (hu) 2010-06-17 2018-10-29 Codexis Inc Biokatalizátorok és módszerek (S)-3(1-aminoetil)-fenol szintéziséhez
CN103313712B (zh) 2010-11-15 2016-10-26 艾吉因生物股份有限公司 用于治疗认知障碍的哒嗪衍生物、组合物和方法
PT2468274E (pt) 2010-12-14 2015-09-21 Acino Ag Sistema terapêutico transdérmico para a administração de uma substância ativa
CN102786441B (zh) * 2011-05-18 2013-11-13 浙江海正药业股份有限公司 利凡斯的明的制备方法、其中间体以及中间体的制备方法
US9585862B2 (en) 2011-05-20 2017-03-07 Sk Chemicals Co., Ltd. Patch containing rivastigmine
AR082640A1 (es) * 2011-08-25 2012-12-19 Amarin Technologies S A Un dispositivo para la administracion transdermal de compuestos alcalinos susceptibles a la degradacion en su forma no salificada
US9333182B2 (en) 2011-08-31 2016-05-10 Sekisui Medical Co., Ltd. Adhesive patch
CN103073456B (zh) * 2011-10-26 2014-03-19 连云港润众制药有限公司 重酒石酸卡巴拉汀中间体的制备方法
EP2594261A1 (en) 2011-11-18 2013-05-22 Labtec GmbH Composition for transdermal administration of rivastigmine
WO2013142339A1 (en) 2012-03-23 2013-09-26 Novartis Ag Transdermal therapeutic system and method
ES2449215B1 (es) * 2012-09-17 2014-07-14 Galenicum Health S.L. Solución oral de (S)-3-[1-(dimetilamino)etil]fenil N-etil-N-metilcarbamato
KR20140038237A (ko) 2012-09-20 2014-03-28 에스케이케미칼주식회사 리바스티그민의 안정성이 개선된 의약품
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
CN103896787A (zh) * 2012-12-26 2014-07-02 江苏康倍得药业有限公司 一种卡巴拉汀前体[1-(3-甲氧基苯基)乙基]二甲胺的制备方法
WO2014111790A2 (en) 2013-01-15 2014-07-24 Zydus Technologies Limited Stable transdermal pharmaceutical drug delivery system comprising rivastigmine
EP3827820A1 (en) 2013-03-15 2021-06-02 The Johns Hopkins University Brivaracetam for improving cognitive function
US11160785B2 (en) 2013-03-15 2021-11-02 Agenebio Inc. Methods and compositions for improving cognitive function
CN103319374B (zh) * 2013-06-09 2015-04-22 无锡佰翱得生物科学有限公司 一种(s)-卡巴拉汀的不对称合成方法
TW201540301A (zh) 2013-08-16 2015-11-01 Takeda Gmbh 以ｐｄｅ４抑制劑治療認知損傷
US10329301B2 (en) 2013-12-20 2019-06-25 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
HK1251980B (en) 2015-05-22 2020-07-10 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
CN113264939A (zh) 2015-06-19 2021-08-17 艾吉因生物股份有限公司 用于治疗认知损害的苯并二氮杂环庚三烯衍生物、组合物和方法
BR112019012821A2 (pt) 2016-12-19 2019-11-26 Agenebio, Inc. derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
EA202190076A1 (ru) 2018-06-19 2021-09-22 Эйджинбайо, Инк. Производные бензодиазепина, композиции и способы лечения когнитивных нарушений
KR20200035359A (ko) 2018-09-26 2020-04-03 캐딜라 파마슈티클즈 리미티드 리바스티그민 제조용 중간체의 합성
EP4572852A1 (en) 2022-08-19 2025-06-25 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment
WO2025038382A1 (en) 2023-08-11 2025-02-20 Momentive Performance Materials Inc. Pharmaceutical adhesive compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4469700A (en) * 1981-06-19 1984-09-04 Lowell M. Somers Benzoylecgonine or benzoylnorecgonine as active agents for the treatment of rheumatoid arthritis
IL74497A (en) * 1985-03-05 1990-02-09 Proterra Ag Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives
NL195004C (nl) * 1987-03-04 2003-11-04 Novartis Ag Fenylcarbamaat bevattend farmaceutisch preparaat.

Also Published As

Publication number Publication date
IT8847693A0 (it) 1988-03-04
LU87150A1 (fr) 1988-11-17
JPS63238054A (ja) 1988-10-04
LU90297I2 (fr) 1998-12-07
CA1307003C (en) 1992-09-01
GB2203040A (en) 1988-10-12
NZ223714A (en) 1994-05-26
IL85609A (en) 1992-07-15
JP2625478B2 (ja) 1997-07-02
BE1001467A3 (fr) 1989-11-07
CY1735A (en) 1994-06-03
SE8800731A0 (sv) 1988-09-05
HK110093A (en) 1993-10-29
NL8800436A (nl) 1988-10-03
AU618949B2 (en) 1992-01-16
NL195004B (nl) 2003-07-01
GB8804888D0 (en) 1988-03-30
AU1255488A (en) 1988-09-08
HUT49325A (en) 1989-09-28
CS411091A3 (en) 1992-12-16
SE8800731L (sv) 1988-09-05
HU201906B (en) 1991-01-28
CH675720A5 (cg-RX-API-DMAC10.html) 1990-10-31
FI880972L (fi) 1988-09-05
IE61714B1 (en) 1994-11-30
IE880583L (en) 1988-09-04
FR2611707A1 (fr) 1988-09-09
US5602176A (en) 1997-02-11
FI880972A0 (fi) 1988-03-02
ES2010527A6 (es) 1989-11-16
GR1000023B (el) 1990-01-31
FI89165B (fi) 1993-05-14
JPH09118617A (ja) 1997-05-06
MY103225A (en) 1993-05-29
KR0133686B1 (ko) 1998-04-21
SE8800731D0 (sv) 1988-03-02
GB2203040B (en) 1990-10-24
DK175762B1 (da) 2005-02-14
IL85609A0 (en) 1988-08-31
JP2859225B2 (ja) 1999-02-17
GR880100125A (en) 1989-01-31
DK112588A (da) 1988-09-05
AT394190B (de) 1992-02-10
KR880011088A (ko) 1988-10-26
IT1219853B (it) 1990-05-24
NL195004C (nl) 2003-11-04
GB2203040C (en) 2014-07-30
PT86875B (pt) 1992-05-29
FR2611707B1 (fr) 1990-04-20
ATA55188A (de) 1991-08-15
ZA881584B (en) 1989-11-29
DK112588D0 (da) 1988-03-02
JPH09165362A (ja) 1997-06-24
FI89165C (fi) 1993-08-25
PT86875A (pt) 1988-04-01

Similar Documents

Publication Publication Date Title
SA93140384B1 (ar) كربامات الفينيل
DE60037664T2 (de) Langkettige n-alkyl verbindungen und deren oxa-derivate zur verwendung als anitvirale mittel
US4871774A (en) Medical treatment
KR101996245B1 (ko) 선택적 s1p1 수용체 아고니스트를 포함하는 약학 조합물
DE3805744C2 (de) Phenylcarbamate zur Hemmung der Acetylcholinesterase
CA2125776A1 (en) Pharmaceutical composition and process for the preparation thereof
DE60312874T2 (de) Kombinationstherapie mit verwendung eines serotonin-wiederaufnahmehemmers
JP2906339B2 (ja) 活性成分としてデヒドロエボジアミン−ＨＣｌを含有する記憶増強および抗痴呆剤
SE9901572D0 (sv) New compounds
NL195081C (nl) Fenylcarbamaat.
DE3844992B4 (de) Hydrogentartrat eines Phenylcarbamats
MXPA02006376A (es) Uso de trimebutina para tratar dolor.
US6121328A (en) Racemic propranolol
Walker et al. Pharmacological and toxicological activity of RSD921, a novel sodium channel blocker
US20210308103A1 (en) Task-1 inhibitors for treatment of atrial arrhythmias
EP3049075A2 (en) Laquinimod combination therapy for treatment of multiple sclerosis
CA1280695C (en) Nalbuphine-local anesthetic analgesic composition and method of producing analgesia
PL154777B1 (pl) Sposób wytwarzania nowego fenylokarbaminianu